Siegfried
Private Company
Funding information not available
Overview
Siegfried is a well-established, publicly traded CDMO with a strong global footprint and a deep expertise in small molecules, drug delivery, and biologics manufacturing. The company demonstrates consistent profitable growth, supported by strategic acquisitions like the planned expansion of US small molecule capacity and investments in areas such as ophthalmic drugs and viral vectors (via DINAMIQS). Its integrated service model, long-term client relationships, and commitment to sustainable production position it as a trusted partner in the pharmaceutical supply chain.
Technology Platform
Integrated CDMO services spanning drug substance (API) and drug product (finished dosage) development and manufacturing for small molecules, drug delivery systems, and biologics (including viral vectors). Expertise in process development, optimization, scale-up, and sustainable/green chemistry.
Opportunities
Risk Factors
Competitive Landscape
Siegfried competes in a fragmented but consolidating global CDMO market against large players like Lonza, Catalent, Thermo Fisher Scientific (Patheon), and Samsung Biologics, as well as numerous specialized firms. Its competitive edge lies in its integrated drug substance-to-product offering, over 150 years of technical heritage, strong small molecule expertise, and strategic investments in high-growth biologics capacity.